Headlines about BioMerieux (OTCMKTS:BMXMF) have trended somewhat positive on Friday, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by monitoring more than 6,000 news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. BioMerieux earned a media sentiment score of 2.00 on their scale. InfoTrie also assigned media coverage about the company an news buzz score of 10 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock’s share price in the immediate future.
BMXMF stock opened at $69.25 on Friday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.30 and a current ratio of 1.99. BioMerieux has a 52-week low of $69.25 and a 52-week high of $96.25.
Separately, Zacks Investment Research raised shares of BioMerieux from a “sell” rating to a “hold” rating in a research note on Monday, September 10th.
WARNING: “Somewhat Positive Media Coverage Extremely Likely to Affect BioMerieux (BMXMF) Share Price” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/12/07/somewhat-positive-media-coverage-extremely-likely-to-affect-biomerieux-bmxmf-share-price.html.
bioMérieux SA provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases. The company offers microbiology technology that involves culturing biological samples; and immunoassays technology based on antigen-antibody reaction, detects and measures infectious agents, such as bacteria, viruses, and parasites, as well as measures the specific biomarkers of various pathologies, such as metabolic, hormonal, infectious, etc.
Recommended Story: What is a stock split?
Receive News & Ratings for BioMerieux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMerieux and related companies with MarketBeat.com's FREE daily email newsletter.